We rank companies based on fund manager, research analyst and news sentiment
BCRX stock icon

BioCryst Pharmaceuticals
BCRX

$4.5
1.97%
 

About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Employees: 531

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 4 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

365% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $2.9M

7% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 76

3% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 31

0% more funds holding

Funds holding: 231 [Q3] → 232 (+1) [Q4]

6.0% less ownership

Funds ownership: 92.33% [Q3] → 86.33% (-6.0%) [Q4]

14% less capital invested

Capital invested by funds: $1.24B [Q3] → $1.06B (-$179M) [Q4]

17% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 5 (-1) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$10
122%
upside
Avg. target
$11.5
156%
upside
High target
$12
167%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Serge Belanger
167%upside
$12
Buy
Reiterated
10 Apr 2024
Needham
Serge Belanger
167%upside
$12
Buy
Reiterated
8 Jan 2024
JP Morgan
Jessica Fye
122%upside
$10
Overweight
Reinstated
20 Nov 2023
Needham
Serge Belanger
167%upside
$12
Buy
Reiterated
6 Nov 2023

Financial journalist opinion

Based on 3 articles about BCRX published over the past 30 days